Healthcare -
Biotechnology - NASDAQ - US
$ 6.54
4.81 %
$ 1.05 B
Market Cap
-5.32
P/E
1. INTRINSIC VALUE
Balance Sheet
Novavax, Inc.
| Current Assets | 1.13 B |
| Cash & Short-Term Investments | 923 M |
| Receivables | 108 M |
| Other Current Assets | 97.5 M |
| Non-Current Assets | 431 M |
| Long-Term Investments | 0 |
| PP&E | 300 M |
| Other Non-Current Assets | 131 M |
| Current Liabilities | 1.15 B |
| Accounts Payable | 41.6 M |
| Short-Term Debt | 7.01 M |
| Other Current Liabilities | 1.11 B |
| Non-Current Liabilities | 1.03 B |
| Long-Term Debt | 223 M |
| Other Non-Current Liabilities | 806 M |
EFFICIENCY
Earnings Waterfall
Novavax, Inc.
| Revenue | 682 M |
| Cost Of Revenue | 203 M |
| Gross Profit | 479 M |
| Operating Expenses | 728 M |
| Operating Income | -249 M |
| Other Expenses | -61.4 M |
| Net Income | -187 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Novavax, Inc.
| Net Income | -187 M |
| Depreciation & Amortization | 48.5 M |
| Capital Expenditures | -13.1 M |
| Stock-Based Compensation | 48.2 M |
| Change in Working Capital | 48.5 M |
| Others | 22.2 M |
| Free Cash Flow | -100 M |
Wall Street Analysts Price Targets
Novavax, Inc.
Wall Street analysts predict an average 1-year price target for NVAX of $22.2 , with forecasts ranging from
a
low of
$14 to a high of $31 .
NVAX Lowest Price Target
Wall Street Target
14 USD
114.07%
NVAX Average Price Target
Wall Street Target
22.2 USD
239.45%
NVAX Highest Price Target
Wall Street Target
31 USD
374.01%
4. DIVIDEND
ANALYSIS
NVAX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Novavax, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
120 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.07 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
zacks.com
- 1 week ago
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $5.98, marking a -0.33% move from the previous day.
zacks.com
- 2 weeks ago
FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports
The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
reuters.com
- 2 weeks ago
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
zacks.com
- 2 weeks ago
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
youtube.com
- 2 weeks ago
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
fastcompany.com
- 2 weeks ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
nypost.com
- 2 weeks ago
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
cnbc.com
- 2 weeks ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
zacks.com
- 2 weeks ago
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments.
reuters.com
- 2 weeks ago
Why Novavax (NVAX) Dipped More Than Broader Market Today
Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day.
zacks.com
- 2 weeks ago
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $7.91, denoting a -0.57% change from the preceding trading day.
zacks.com
- 4 weeks ago
8. Profile
Summary
Novavax, Inc. NVAX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.05 B
Dividend Yield
0.00%
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Contact
21 Firstfield Road, Gaithersburg, MD, 20878
https://www.novavax.com
IPO
Date
Dec. 5, 1995
Employees
952
Officers
Mr. Ian J. Watkins
Executive Vice President & Chief Human Resources Officer
Mr. John Charles Jacobs M.B.A.
President, Chief Executive Officer & Director
Mr. Mark Casey
Executive Vice President, Chief Legal Officer & Corporate Secretary
Mr. Troy Morgan Esq., J.D.
Senior Vice President, Deputy General Counsel & Chief Compliance Officer
Ms. Silvia Taylor M.B.A.
Executive Vice President and Chief Corporate Affairs & Advocacy Officer
Dr. Henrietta Ukwu FACP FRAPS, M.D.
Executive Vice President & Chief Regulatory Officer
Ms. Erika S. Trahan
Associate Director of Investor & Public Relations
Mr. James Patrick Kelly C.F.A.
Executive Vice President, Chief Financial Officer & Treasurer
Mr. John Joseph Trizzino B.S., M.B.A.
President & Chief Operating Officer
Mr. Richard P. Crowley
Executive Vice President & Chief Operating Officer